Advertisement

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Feb 28, 2012-- TYRX(R), Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections, today announcedthe launch of its new patient education web site, HeartDeviceInfection.com.

HeartDeviceInfection.com, targeting patients and caregivers, has been created to raise awareness of surgical site infection associated with cardiac implantable electronic devices (CIEDs) including pacemakers and implantable defibrillators, and to offer information and resources for reducing that risk.

"With CIED infections growing much faster than implantations, being very expensive to treat, and having a one-year mortality rate of 30%, it is very important to widely and rapidly educate patients and caregivers that there is technology available that can help prevent these infections", stated Dr. Charles Kinder, Director, Heart Rhythm Program, Heart Care Centers of Illinois.

By launching HeartDeviceInfection.com, we are able to reach a very broad and diverse audience of patients and caregivers looking for information to address their heart health concerns.

HeartDeviceInfection.com will serve as an important resource to help reduce the number of cardiac device infections impacting patients and the heath care system," stated TYRX CEO, Robert White.

About TYRX, Inc.

TYRX, Inc. commercializes innovative, implantable combination drug+device products focused on infection control, including the AIGISRx(R) Antibacterial Envelope, designed to reduce surgical-site infections associated with Cardiac Implantable Electronic Devices (CIEDs). AIGISRx products contain antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in implantable pacemaker and defibrillator related endocarditis, including "superbugs" or MRSA*. Following commercial release, the AIGISRx Envelope has been used in over 25,000 patients nationwide. The company estimates that over 2% of all U.S. implantable pacemaker and defibrillator patients in 2012 will receive an AIGISRx product during their procedure.

TYRX, Inc. is an ISO 13485:2003 certified medical device manufacturer and its products utilize technology licensed exclusively from Rutgers, Baylor College of Medicine, and The University of Texas M. D. Anderson Cancer Center. For more information, please visit http://www.tyrx.com.

* Based upon preclinical in vitro and in vivo data. Data on file at TYRX and published in PACE 2009; 32(7) 898-907.

CONTACT: TYRX, Inc.

Robert White, 732-246-8676 President and Chief Executive Officer info@TYRX.com KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY MEDICAL DEVICES SOURCE: TYRX, Inc.

Copyright Business Wire 2012 PUB: 02/28/2012 08:00 AM/DISC: 02/28/2012 08:00 AM http://www.businesswire.com/news/home/20120228005078/

Advertisement
Advertisement